Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 26;161(5):515-522.
doi: 10.1001/jamadermatol.2025.0001. Online ahead of print.

Risk of Major Adverse Cardiovascular Events Following Nicotinamide Exposure

Lee Wheless  1   2   3 , Ranya Guennoun  4 , Basia Michalski-McNeely  4 , Katlyn M Gonzalez  5 , Rachel Weiss  2 , Siwei Zhang  6 , Lydia Yao  6 , Chris Madden  7 , Hua-Chang Chen  6 , Jefferson L Triozzi  8 , Ran Tao  6 , Otis Wilson  1 , Quinn S Wells  9 , Adriana Hung  1   8 , Kristin Bibee  10 , Rebecca I Hartman  11   12 , Yaomin Xu  6 ; VA Million Veteran Program
Collaborators, Affiliations

Risk of Major Adverse Cardiovascular Events Following Nicotinamide Exposure

Lee Wheless et al. JAMA Dermatol. .

Abstract

Importance: Nicotinamide metabolites have recently been implicated in increased risk of major cardiovascular events (MACE). Supportive data about clinical risk of MACE for nicotinamide users is lacking.

Objective: To determine whether nicotinamide use results in an increase of MACE.

Design, setting, and participants: This study used retrospective electronic health record data of 2 patient cohorts, the Vanderbilt University Medical Center (VUMC) and Million Veteran Program (MVP). The risk of MACE in patients exposed to nicotinamide was compared with the risk of MACE in unexposed patients. In the VUMC cohort, patients were either exposed to nicotinamide based on keyword entry for nicotinamide or niacinamide and manual review of medical records or were unexposed but had documented recommendation for use. In the MVP cohort, those exposed to nicotinamide were matched via propensity scores to those who were not exposed. Data were collected from January 1989 to February 2024, and data were analyzed from March to December 2024.

Exposures: The primary exposure for the VUMC cohort was a confirmed exposure to nicotinamide on medical record review. The primary exposure for the MVP cohort was medication entry for nicotinamide or niacinamide.

Main outcomes and measures: The primary outcome was development of MACE based on a validated phenotype.

Results: Of 13 108 included patients, 11 926 (91.0%) were male, and the mean (SD) age was 66.8 (11.5) years. In the VUMC cohort, 1228 patients were exposed to nicotinamide and 253 were unexposed; in the MVP cohort, 4063 were exposed and 7564 were not. A total of 5291 had exposure to nicotinamide. Neither cohort had significant differences in mean age, sex, race, or ethnicity between the nicotinamide exposed and unexposed groups. There was no difference in the cumulative incidence of MACE after nicotinamide exposure in either the VUMC cohort or MVP cohorts. In adjusted cause-specific models stratified by history of prior MACE, there was no significant association between nicotinamide exposure and the primary outcome of MACE in either the VUMC cohort (no prior MACE: hazard ratio [HR], 2.02; 95% CI, 0.81-5.05; prior MACE: HR, 0.46; 95% CI, 0.22-0.95) or MVP cohort (no prior MACE: HR, 1.07; 95% CI, 0.75-1.17; prior MACE: HR, 1.04; 95% CI, 0.53-2.06).

Conclusions and relevance: In this retrospective cohort study of 13 108 adults from 2 different patient populations, there was no increased risk of MACE in patients with nicotinamide exposure.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wheless reported grants from the Department of Veterans Affairs during the conduct of the study. Dr Triozzi reported grants from the National Institutes of Health during the conduct of the study. Dr Hung reported grants from the Department of Veterans Affairs during the conduct of the study. Dr Hartman reported grants from the Department of Veterans Affairs and grants from the Department of Defense during the conduct of the study; grants from Dermasensor; as well as personal fees from Evereden, Oasis Pharmaceuticals, Almirall, MJH Life Sciences, and Med Learning Group outside the submitted work. No other disclosures were reported.

Update of

References

    1. Chen AC, Martin AJ, Choy B, et al. . A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618-1626. doi:10.1056/NEJMoa1506197 - DOI - PubMed
    1. Chung EYM, Palmer SC, Strippoli GFM. Interventions to prevent nonmelanoma skin cancers in recipients of a solid organ transplant: systematic review of randomized controlled trials. Transplantation. 2019;103(6):1206-1215. doi:10.1097/TP.0000000000002641 - DOI - PubMed
    1. Willenbrink TJ, Jambusaria-Pahlajani A, Arron S, Seckin D, Harwood CA, Proby CM. Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2019;33(suppl 8):57-60. doi:10.1111/jdv.15843 - DOI - PubMed
    1. Allen NC, Martin AJ, Snaidr VA, et al. . Nicotinamide for skin-cancer chemoprevention in transplant recipients. N Engl J Med. 2023;388(9):804-812. doi:10.1056/NEJMoa2203086 - DOI - PubMed
    1. Ferrell M, Wang Z, Anderson JT, et al. . A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med. 2024;30(2):424-434. doi:10.1038/s41591-023-02793-8 - DOI - PMC - PubMed

LinkOut - more resources